nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—Graves' disease	0.696	1	CtDrD
Sorafenib—CYP2B6—Methimazole—Graves' disease	0.0509	0.282	CbGbCtD
Sorafenib—CYP2C19—Methimazole—Graves' disease	0.0323	0.179	CbGbCtD
Sorafenib—CYP1A2—Methimazole—Graves' disease	0.0298	0.166	CbGbCtD
Sorafenib—CYP2C9—Methimazole—Graves' disease	0.0269	0.149	CbGbCtD
Sorafenib—CYP2D6—Methimazole—Graves' disease	0.0246	0.136	CbGbCtD
Sorafenib—CYP3A4—Methimazole—Graves' disease	0.0156	0.0868	CbGbCtD
Sorafenib—Allergic cutaneous angiitis—Propylthiouracil—Graves' disease	0.00541	0.128	CcSEcCtD
Sorafenib—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.00356	0.084	CcSEcCtD
Sorafenib—Leukocytoclastic vasculitis—Propylthiouracil—Graves' disease	0.0035	0.0828	CcSEcCtD
Sorafenib—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00243	0.0574	CcSEcCtD
Sorafenib—CDKL3—adipose tissue—Graves' disease	0.00194	0.0328	CbGeAlD
Sorafenib—Hepatic failure—Propylthiouracil—Graves' disease	0.00139	0.0328	CcSEcCtD
Sorafenib—MAPK15—thyroid gland—Graves' disease	0.00138	0.0234	CbGeAlD
Sorafenib—Renal failure acute—Propylthiouracil—Graves' disease	0.00135	0.0319	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00132	0.0312	CcSEcCtD
Sorafenib—CDK7—connective tissue—Graves' disease	0.00122	0.0206	CbGeAlD
Sorafenib—Neuropathy peripheral—Methimazole—Graves' disease	0.00111	0.0262	CcSEcCtD
Sorafenib—Jaundice—Methimazole—Graves' disease	0.0011	0.026	CcSEcCtD
Sorafenib—ZAK—eye—Graves' disease	0.00109	0.0184	CbGeAlD
Sorafenib—HIPK3—connective tissue—Graves' disease	0.00103	0.0174	CbGeAlD
Sorafenib—MAPK11—adipose tissue—Graves' disease	0.000948	0.016	CbGeAlD
Sorafenib—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.000943	0.0223	CcSEcCtD
Sorafenib—Jaundice—Propylthiouracil—Graves' disease	0.000937	0.0221	CcSEcCtD
Sorafenib—CDK7—adipose tissue—Graves' disease	0.000932	0.0158	CbGeAlD
Sorafenib—TAOK2—pituitary gland—Graves' disease	0.000929	0.0157	CbGeAlD
Sorafenib—TAOK2—adipose tissue—Graves' disease	0.000925	0.0157	CbGeAlD
Sorafenib—EPHX2—eye—Graves' disease	0.000914	0.0155	CbGeAlD
Sorafenib—Alopecia—Methimazole—Graves' disease	0.000897	0.0212	CcSEcCtD
Sorafenib—FLT3—connective tissue—Graves' disease	0.000874	0.0148	CbGeAlD
Sorafenib—Haemoglobin—Propylthiouracil—Graves' disease	0.000868	0.0205	CcSEcCtD
Sorafenib—Haemorrhage—Propylthiouracil—Graves' disease	0.000863	0.0204	CcSEcCtD
Sorafenib—FLT4—eye—Graves' disease	0.000824	0.0139	CbGeAlD
Sorafenib—MAPK11—thyroid gland—Graves' disease	0.00082	0.0139	CbGeAlD
Sorafenib—CDK7—thyroid gland—Graves' disease	0.000807	0.0137	CbGeAlD
Sorafenib—ZAK—adipose tissue—Graves' disease	0.000806	0.0136	CbGeAlD
Sorafenib—TAOK2—thyroid gland—Graves' disease	0.000801	0.0135	CbGeAlD
Sorafenib—AURKC—thyroid gland—Graves' disease	0.000795	0.0134	CbGeAlD
Sorafenib—HIPK3—pituitary gland—Graves' disease	0.000792	0.0134	CbGeAlD
Sorafenib—Leukopenia—Methimazole—Graves' disease	0.000791	0.0187	CcSEcCtD
Sorafenib—HIPK3—adipose tissue—Graves' disease	0.000789	0.0133	CbGeAlD
Sorafenib—Alopecia—Propylthiouracil—Graves' disease	0.000763	0.018	CcSEcCtD
Sorafenib—Myalgia—Methimazole—Graves' disease	0.000752	0.0178	CcSEcCtD
Sorafenib—Arthralgia—Methimazole—Graves' disease	0.000752	0.0178	CcSEcCtD
Sorafenib—MKNK2—eye—Graves' disease	0.000746	0.0126	CbGeAlD
Sorafenib—TIE1—adipose tissue—Graves' disease	0.000737	0.0125	CbGeAlD
Sorafenib—MKNK1—eye—Graves' disease	0.000736	0.0125	CbGeAlD
Sorafenib—Dysgeusia—Propylthiouracil—Graves' disease	0.000736	0.0174	CcSEcCtD
Sorafenib—MKNK2—connective tissue—Graves' disease	0.000719	0.0122	CbGeAlD
Sorafenib—BRAF—pituitary gland—Graves' disease	0.00071	0.012	CbGeAlD
Sorafenib—BRAF—adipose tissue—Graves' disease	0.000707	0.012	CbGeAlD
Sorafenib—Thrombocytopenia—Methimazole—Graves' disease	0.000706	0.0167	CcSEcCtD
Sorafenib—RET—connective tissue—Graves' disease	0.000701	0.0119	CbGeAlD
Sorafenib—ZAK—thyroid gland—Graves' disease	0.000698	0.0118	CbGeAlD
Sorafenib—HIPK3—thyroid gland—Graves' disease	0.000683	0.0116	CbGeAlD
Sorafenib—EPHX2—pituitary gland—Graves' disease	0.000678	0.0115	CbGeAlD
Sorafenib—EPHX2—adipose tissue—Graves' disease	0.000675	0.0114	CbGeAlD
Sorafenib—RALBP1—eye—Graves' disease	0.000674	0.0114	CbGeAlD
Sorafenib—Leukopenia—Propylthiouracil—Graves' disease	0.000673	0.0159	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methimazole—Graves' disease	0.000657	0.0155	CcSEcCtD
Sorafenib—FLT1—eye—Graves' disease	0.000641	0.0108	CbGeAlD
Sorafenib—Myalgia—Propylthiouracil—Graves' disease	0.00064	0.0151	CcSEcCtD
Sorafenib—Arthralgia—Propylthiouracil—Graves' disease	0.00064	0.0151	CcSEcCtD
Sorafenib—TIE1—thyroid gland—Graves' disease	0.000638	0.0108	CbGeAlD
Sorafenib—RAF1—eye—Graves' disease	0.000637	0.0108	CbGeAlD
Sorafenib—Dyspepsia—Methimazole—Graves' disease	0.000635	0.015	CcSEcCtD
Sorafenib—FLT1—connective tissue—Graves' disease	0.000617	0.0104	CbGeAlD
Sorafenib—RAF1—connective tissue—Graves' disease	0.000614	0.0104	CbGeAlD
Sorafenib—BRAF—thyroid gland—Graves' disease	0.000612	0.0103	CbGeAlD
Sorafenib—FLT4—adipose tissue—Graves' disease	0.000609	0.0103	CbGeAlD
Sorafenib—FGFR1—pituitary gland—Graves' disease	0.000603	0.0102	CbGeAlD
Sorafenib—FGFR1—adipose tissue—Graves' disease	0.000601	0.0102	CbGeAlD
Sorafenib—Thrombocytopenia—Propylthiouracil—Graves' disease	0.0006	0.0142	CcSEcCtD
Sorafenib—EPHX2—thyroid gland—Graves' disease	0.000585	0.00989	CbGeAlD
Sorafenib—PDGFRA—connective tissue—Graves' disease	0.000578	0.00979	CbGeAlD
Sorafenib—Urticaria—Methimazole—Graves' disease	0.000573	0.0135	CcSEcCtD
Sorafenib—MAP3K7—pituitary gland—Graves' disease	0.000571	0.00966	CbGeAlD
Sorafenib—Body temperature increased—Methimazole—Graves' disease	0.00057	0.0135	CcSEcCtD
Sorafenib—MAP3K7—adipose tissue—Graves' disease	0.000569	0.00962	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.000559	0.0132	CcSEcCtD
Sorafenib—MKNK2—pituitary gland—Graves' disease	0.000554	0.00937	CbGeAlD
Sorafenib—MKNK2—adipose tissue—Graves' disease	0.000551	0.00933	CbGeAlD
Sorafenib—MKNK1—pituitary gland—Graves' disease	0.000547	0.00925	CbGeAlD
Sorafenib—MKNK1—adipose tissue—Graves' disease	0.000544	0.00921	CbGeAlD
Sorafenib—KDR—eye—Graves' disease	0.000542	0.00916	CbGeAlD
Sorafenib—RET—pituitary gland—Graves' disease	0.00054	0.00913	CbGeAlD
Sorafenib—Dyspepsia—Propylthiouracil—Graves' disease	0.00054	0.0128	CcSEcCtD
Sorafenib—CSF1R—eye—Graves' disease	0.000528	0.00894	CbGeAlD
Sorafenib—FLT4—thyroid gland—Graves' disease	0.000527	0.00892	CbGeAlD
Sorafenib—KDR—connective tissue—Graves' disease	0.000522	0.00883	CbGeAlD
Sorafenib—FGFR1—thyroid gland—Graves' disease	0.00052	0.0088	CbGeAlD
Sorafenib—Pruritus—Methimazole—Graves' disease	0.00051	0.0121	CcSEcCtD
Sorafenib—CSF1R—connective tissue—Graves' disease	0.000509	0.00862	CbGeAlD
Sorafenib—RALBP1—pituitary gland—Graves' disease	0.0005	0.00846	CbGeAlD
Sorafenib—RALBP1—adipose tissue—Graves' disease	0.000498	0.00842	CbGeAlD
Sorafenib—MAP3K7—thyroid gland—Graves' disease	0.000492	0.00833	CbGeAlD
Sorafenib—Urticaria—Propylthiouracil—Graves' disease	0.000487	0.0115	CcSEcCtD
Sorafenib—Body temperature increased—Propylthiouracil—Graves' disease	0.000485	0.0115	CcSEcCtD
Sorafenib—MKNK2—thyroid gland—Graves' disease	0.000477	0.00807	CbGeAlD
Sorafenib—FLT1—pituitary gland—Graves' disease	0.000476	0.00805	CbGeAlD
Sorafenib—FLT1—adipose tissue—Graves' disease	0.000474	0.00801	CbGeAlD
Sorafenib—RAF1—pituitary gland—Graves' disease	0.000473	0.008	CbGeAlD
Sorafenib—MKNK1—thyroid gland—Graves' disease	0.000471	0.00797	CbGeAlD
Sorafenib—RAF1—adipose tissue—Graves' disease	0.000471	0.00797	CbGeAlD
Sorafenib—EPHB6—pituitary gland—Graves' disease	0.00047	0.00795	CbGeAlD
Sorafenib—PDGFRB—eye—Graves' disease	0.000469	0.00793	CbGeAlD
Sorafenib—EPHB6—adipose tissue—Graves' disease	0.000468	0.00792	CbGeAlD
Sorafenib—RET—thyroid gland—Graves' disease	0.000465	0.00787	CbGeAlD
Sorafenib—KIT—connective tissue—Graves' disease	0.000462	0.00782	CbGeAlD
Sorafenib—Vomiting—Methimazole—Graves' disease	0.000459	0.0108	CcSEcCtD
Sorafenib—Rash—Methimazole—Graves' disease	0.000455	0.0107	CcSEcCtD
Sorafenib—Dermatitis—Methimazole—Graves' disease	0.000454	0.0107	CcSEcCtD
Sorafenib—Headache—Methimazole—Graves' disease	0.000452	0.0107	CcSEcCtD
Sorafenib—PDGFRB—connective tissue—Graves' disease	0.000452	0.00764	CbGeAlD
Sorafenib—STK10—adipose tissue—Graves' disease	0.000448	0.00758	CbGeAlD
Sorafenib—PDGFRA—adipose tissue—Graves' disease	0.000444	0.00751	CbGeAlD
Sorafenib—Pruritus—Propylthiouracil—Graves' disease	0.000434	0.0102	CcSEcCtD
Sorafenib—RALBP1—thyroid gland—Graves' disease	0.000431	0.00729	CbGeAlD
Sorafenib—Nausea—Methimazole—Graves' disease	0.000428	0.0101	CcSEcCtD
Sorafenib—FLT1—thyroid gland—Graves' disease	0.00041	0.00694	CbGeAlD
Sorafenib—RAF1—thyroid gland—Graves' disease	0.000408	0.0069	CbGeAlD
Sorafenib—EPHB6—thyroid gland—Graves' disease	0.000405	0.00686	CbGeAlD
Sorafenib—KDR—pituitary gland—Graves' disease	0.000402	0.0068	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—Graves' disease	0.000402	0.0068	CbGeAlD
Sorafenib—KDR—adipose tissue—Graves' disease	0.0004	0.00677	CbGeAlD
Sorafenib—MAP2K5—adipose tissue—Graves' disease	0.0004	0.00677	CbGeAlD
Sorafenib—CSF1R—pituitary gland—Graves' disease	0.000392	0.00664	CbGeAlD
Sorafenib—CSF1R—adipose tissue—Graves' disease	0.000391	0.00661	CbGeAlD
Sorafenib—Vomiting—Propylthiouracil—Graves' disease	0.00039	0.00921	CcSEcCtD
Sorafenib—STK10—thyroid gland—Graves' disease	0.000388	0.00657	CbGeAlD
Sorafenib—Rash—Propylthiouracil—Graves' disease	0.000387	0.00913	CcSEcCtD
Sorafenib—Dermatitis—Propylthiouracil—Graves' disease	0.000386	0.00912	CcSEcCtD
Sorafenib—Headache—Propylthiouracil—Graves' disease	0.000384	0.00907	CcSEcCtD
Sorafenib—PDGFRA—thyroid gland—Graves' disease	0.000384	0.0065	CbGeAlD
Sorafenib—Nausea—Propylthiouracil—Graves' disease	0.000364	0.0086	CcSEcCtD
Sorafenib—KIT—pituitary gland—Graves' disease	0.000356	0.00603	CbGeAlD
Sorafenib—KIT—adipose tissue—Graves' disease	0.000355	0.006	CbGeAlD
Sorafenib—PDGFRB—pituitary gland—Graves' disease	0.000348	0.00589	CbGeAlD
Sorafenib—KDR—thyroid gland—Graves' disease	0.000347	0.00586	CbGeAlD
Sorafenib—MAP2K5—thyroid gland—Graves' disease	0.000347	0.00586	CbGeAlD
Sorafenib—PDGFRB—adipose tissue—Graves' disease	0.000346	0.00586	CbGeAlD
Sorafenib—CSF1R—thyroid gland—Graves' disease	0.000338	0.00572	CbGeAlD
Sorafenib—KIT—thyroid gland—Graves' disease	0.000307	0.0052	CbGeAlD
Sorafenib—PDGFRB—thyroid gland—Graves' disease	0.0003	0.00507	CbGeAlD
Sorafenib—ABCC4—adipose tissue—Graves' disease	0.000276	0.00467	CbGeAlD
Sorafenib—HTR2B—adipose tissue—Graves' disease	0.000274	0.00464	CbGeAlD
Sorafenib—ABCC4—thyroid gland—Graves' disease	0.000239	0.00404	CbGeAlD
Sorafenib—HTR2B—thyroid gland—Graves' disease	0.000238	0.00402	CbGeAlD
Sorafenib—CYP2C8—pituitary gland—Graves' disease	0.000201	0.0034	CbGeAlD
Sorafenib—ABCG2—pituitary gland—Graves' disease	0.000196	0.00331	CbGeAlD
Sorafenib—ABCG2—adipose tissue—Graves' disease	0.000195	0.0033	CbGeAlD
Sorafenib—CYP3A5—adipose tissue—Graves' disease	0.000181	0.00306	CbGeAlD
Sorafenib—ABCG2—thyroid gland—Graves' disease	0.000169	0.00285	CbGeAlD
Sorafenib—CYP1A2—thyroid gland—Graves' disease	0.000162	0.00275	CbGeAlD
Sorafenib—ABCB1—pituitary gland—Graves' disease	9.64e-05	0.00163	CbGeAlD
Sorafenib—ABCB1—adipose tissue—Graves' disease	9.6e-05	0.00162	CbGeAlD
Sorafenib—ABCB1—thyroid gland—Graves' disease	8.31e-05	0.00141	CbGeAlD
Sorafenib—MAP2K5—Signaling Pathways—TSHR—Graves' disease	1.78e-05	0.000791	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD8A—Graves' disease	1.78e-05	0.00079	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—IL2RA—Graves' disease	1.77e-05	0.000787	CbGpPWpGaD
Sorafenib—RAF1—Disease—B3GNT2—Graves' disease	1.77e-05	0.000783	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL2RA—Graves' disease	1.76e-05	0.000779	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TSHR—Graves' disease	1.74e-05	0.000771	CbGpPWpGaD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.73e-05	0.000769	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—TSHR—Graves' disease	1.73e-05	0.000769	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.73e-05	0.000767	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL2RA—Graves' disease	1.73e-05	0.000767	CbGpPWpGaD
Sorafenib—PDGFRB—MAPK Signaling Pathway—TNF—Graves' disease	1.73e-05	0.000766	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-DQB1—Graves' disease	1.72e-05	0.000762	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-B—Graves' disease	1.72e-05	0.000762	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-B—Graves' disease	1.71e-05	0.00076	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-E—Graves' disease	1.71e-05	0.000758	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GC—Graves' disease	1.7e-05	0.000754	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—TNF—Graves' disease	1.7e-05	0.000752	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CXCL10—Graves' disease	1.69e-05	0.000748	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GC—Graves' disease	1.69e-05	0.000748	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-A—Graves' disease	1.68e-05	0.000744	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-A—Graves' disease	1.68e-05	0.000744	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFIH1—Graves' disease	1.67e-05	0.000741	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD40—Graves' disease	1.67e-05	0.000741	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	1.65e-05	0.000731	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	1.65e-05	0.000731	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CTLA4—Graves' disease	1.65e-05	0.00073	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	1.63e-05	0.000724	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	1.63e-05	0.000724	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HLA-B—Graves' disease	1.61e-05	0.000713	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD8A—Graves' disease	1.61e-05	0.000712	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	1.6e-05	0.00071	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-A—Graves' disease	1.59e-05	0.000706	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-A—Graves' disease	1.59e-05	0.000704	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IFNG—Graves' disease	1.58e-05	0.000701	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-B—Graves' disease	1.54e-05	0.000685	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	1.54e-05	0.000684	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-E—Graves' disease	1.54e-05	0.000684	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-E—Graves' disease	1.54e-05	0.000684	CbGpPWpGaD
Sorafenib—RAF1—MAPK Signaling Pathway—TNF—Graves' disease	1.54e-05	0.000683	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-DRB1—Graves' disease	1.53e-05	0.00068	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-DRB1—Graves' disease	1.53e-05	0.00068	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-DQB1—Graves' disease	1.53e-05	0.00068	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—B3GNT2—Graves' disease	1.52e-05	0.000674	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—B3GNT2—Graves' disease	1.52e-05	0.000674	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD40—Graves' disease	1.51e-05	0.000668	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD40—Graves' disease	1.51e-05	0.000668	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—TSHR—Graves' disease	1.5e-05	0.000664	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TSHR—Graves' disease	1.49e-05	0.000663	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—IL2RA—Graves' disease	1.49e-05	0.000662	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFIH1—Graves' disease	1.49e-05	0.00066	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTLA4—Graves' disease	1.49e-05	0.000659	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTLA4—Graves' disease	1.49e-05	0.000659	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TSHR—Graves' disease	1.48e-05	0.000656	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—ICAM1—Graves' disease	1.47e-05	0.000652	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—ICAM1—Graves' disease	1.47e-05	0.000652	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-E—Graves' disease	1.46e-05	0.000649	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-E—Graves' disease	1.46e-05	0.000647	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-DRB1—Graves' disease	1.46e-05	0.000645	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-DRB1—Graves' disease	1.45e-05	0.000644	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HLA-B—Graves' disease	1.43e-05	0.000636	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL2RA—Graves' disease	1.43e-05	0.000635	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD8A—Graves' disease	1.43e-05	0.000635	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-A—Graves' disease	1.43e-05	0.000635	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD40—Graves' disease	1.43e-05	0.000634	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD40—Graves' disease	1.43e-05	0.000632	CbGpPWpGaD
Sorafenib—CDK7—Disease—HLA-A—Graves' disease	1.43e-05	0.000632	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IL1B—Graves' disease	1.41e-05	0.000625	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTLA4—Graves' disease	1.41e-05	0.000625	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTLA4—Graves' disease	1.41e-05	0.000623	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—ICAM1—Graves' disease	1.4e-05	0.000619	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—ICAM1—Graves' disease	1.39e-05	0.000618	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.39e-05	0.000616	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-B—Graves' disease	1.38e-05	0.00061	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-DQB1—Graves' disease	1.36e-05	0.000601	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TSHR—Graves' disease	1.35e-05	0.000598	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TSHR—Graves' disease	1.35e-05	0.000598	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—TNF—Graves' disease	1.33e-05	0.000589	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CXCL10—Graves' disease	1.32e-05	0.000585	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-E—Graves' disease	1.31e-05	0.000583	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-DRB1—Graves' disease	1.31e-05	0.00058	CbGpPWpGaD
Sorafenib—MKNK1—Disease—CD4—Graves' disease	1.3e-05	0.000578	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL2RA—Graves' disease	1.29e-05	0.000572	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—B3GNT2—Graves' disease	1.29e-05	0.000572	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD40—Graves' disease	1.29e-05	0.00057	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TSHR—Graves' disease	1.28e-05	0.000567	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—B3GNT2—Graves' disease	1.28e-05	0.000567	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TSHR—Graves' disease	1.28e-05	0.000566	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-A—Graves' disease	1.28e-05	0.000566	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTLA4—Graves' disease	1.27e-05	0.000562	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD8A—Graves' disease	1.27e-05	0.000562	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—ICAM1—Graves' disease	1.25e-05	0.000556	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—CD4—Graves' disease	1.25e-05	0.000554	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GC—Graves' disease	1.25e-05	0.000553	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-DQB1—Graves' disease	1.22e-05	0.000542	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-DQB1—Graves' disease	1.22e-05	0.000542	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GC—Graves' disease	1.22e-05	0.000541	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-B—Graves' disease	1.22e-05	0.00054	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CXCL10—Graves' disease	1.2e-05	0.000532	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-E—Graves' disease	1.17e-05	0.00052	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-DRB1—Graves' disease	1.17e-05	0.000517	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-DQB1—Graves' disease	1.16e-05	0.000515	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-DQB1—Graves' disease	1.16e-05	0.000513	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CXCL10—Graves' disease	1.15e-05	0.000511	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TSHR—Graves' disease	1.15e-05	0.00051	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD40—Graves' disease	1.15e-05	0.000508	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD8A—Graves' disease	1.14e-05	0.000506	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD8A—Graves' disease	1.14e-05	0.000506	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL2RA—Graves' disease	1.14e-05	0.000506	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-A—Graves' disease	1.13e-05	0.000501	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTLA4—Graves' disease	1.13e-05	0.000501	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—CD4—Graves' disease	1.13e-05	0.000499	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—CD4—Graves' disease	1.13e-05	0.000499	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CXCL10—Graves' disease	1.12e-05	0.000498	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CXCL10—Graves' disease	1.12e-05	0.000497	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—ICAM1—Graves' disease	1.12e-05	0.000496	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—TNF—Graves' disease	1.1e-05	0.000489	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-B—Graves' disease	1.1e-05	0.000487	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-B—Graves' disease	1.1e-05	0.000487	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TSHR—Graves' disease	1.1e-05	0.000486	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD8A—Graves' disease	1.08e-05	0.000481	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD4—Graves' disease	1.08e-05	0.00048	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD4—Graves' disease	1.08e-05	0.00048	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD8A—Graves' disease	1.08e-05	0.000479	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CD4—Graves' disease	1.07e-05	0.000474	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CD4—Graves' disease	1.07e-05	0.000473	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	1.07e-05	0.000472	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GC—Graves' disease	1.06e-05	0.000468	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-DQB1—Graves' disease	1.04e-05	0.000462	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-B—Graves' disease	1.04e-05	0.000462	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-B—Graves' disease	1.04e-05	0.000461	CbGpPWpGaD
Sorafenib—BRAF—Disease—HLA-A—Graves' disease	1.03e-05	0.000458	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-DRB1—Graves' disease	1.03e-05	0.000457	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL2RA—Graves' disease	1.03e-05	0.000456	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL2RA—Graves' disease	1.03e-05	0.000456	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD4—Graves' disease	1.03e-05	0.000455	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TSHR—Graves' disease	1.02e-05	0.000454	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD4—Graves' disease	1.02e-05	0.000454	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-A—Graves' disease	1.02e-05	0.000451	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-A—Graves' disease	1.02e-05	0.000451	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—IL2RA—Graves' disease	1.01e-05	0.000447	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—ICAM1—Graves' disease	9.9e-06	0.000439	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL2RA—Graves' disease	9.77e-06	0.000433	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL2RA—Graves' disease	9.75e-06	0.000432	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD8A—Graves' disease	9.74e-06	0.000432	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	9.67e-06	0.000429	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-A—Graves' disease	9.66e-06	0.000428	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL10—Graves' disease	9.66e-06	0.000428	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-A—Graves' disease	9.64e-06	0.000427	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CD4—Graves' disease	9.6e-06	0.000426	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL10—Graves' disease	9.57e-06	0.000424	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—TNF—Graves' disease	9.48e-06	0.00042	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—B3GNT2—Graves' disease	9.45e-06	0.000419	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GC—Graves' disease	9.43e-06	0.000418	CbGpPWpGaD
Sorafenib—KIT—Disease—HLA-A—Graves' disease	9.4e-06	0.000417	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-B—Graves' disease	9.37e-06	0.000415	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-DRB1—Graves' disease	9.3e-06	0.000412	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-DRB1—Graves' disease	9.3e-06	0.000412	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-DQB1—Graves' disease	9.3e-06	0.000412	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—B3GNT2—Graves' disease	9.24e-06	0.00041	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD4—Graves' disease	9.22e-06	0.000409	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GC—Graves' disease	9.2e-06	0.000408	CbGpPWpGaD
Sorafenib—CDK7—Disease—CD4—Graves' disease	9.19e-06	0.000407	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2RA—Graves' disease	9.16e-06	0.000406	CbGpPWpGaD
Sorafenib—KIT—Immune System—ICAM1—Graves' disease	8.93e-06	0.000396	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—ICAM1—Graves' disease	8.93e-06	0.000396	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HLA-A—Graves' disease	8.92e-06	0.000395	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HLA-A—Graves' disease	8.9e-06	0.000394	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TSHR—Graves' disease	8.84e-06	0.000392	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-DRB1—Graves' disease	8.83e-06	0.000391	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2RA—Graves' disease	8.81e-06	0.000391	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-DRB1—Graves' disease	8.8e-06	0.00039	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2RA—Graves' disease	8.78e-06	0.000389	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL10—Graves' disease	8.71e-06	0.000386	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL10—Graves' disease	8.71e-06	0.000386	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD8A—Graves' disease	8.68e-06	0.000385	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-A—Graves' disease	8.68e-06	0.000385	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GC—Graves' disease	8.67e-06	0.000384	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GC—Graves' disease	8.59e-06	0.000381	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2RA—Graves' disease	8.58e-06	0.000381	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2RA—Graves' disease	8.56e-06	0.00038	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CD4—Graves' disease	8.56e-06	0.00038	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—ICAM1—Graves' disease	8.47e-06	0.000376	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—ICAM1—Graves' disease	8.45e-06	0.000375	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-B—Graves' disease	8.35e-06	0.00037	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL10—Graves' disease	8.26e-06	0.000366	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL10—Graves' disease	8.24e-06	0.000366	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD4—Graves' disease	8.22e-06	0.000364	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	8.14e-06	0.000361	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—Graves' disease	8.11e-06	0.00036	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HLA-A—Graves' disease	8.01e-06	0.000355	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—B3GNT2—Graves' disease	8e-06	0.000355	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-DRB1—Graves' disease	7.93e-06	0.000352	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2RA—Graves' disease	7.83e-06	0.000347	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-A—Graves' disease	7.74e-06	0.000343	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—ICAM1—Graves' disease	7.61e-06	0.000338	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IFNG—Graves' disease	7.53e-06	0.000334	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL10—Graves' disease	7.43e-06	0.000329	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	7.39e-06	0.000328	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2RA—Graves' disease	7.38e-06	0.000327	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GC—Graves' disease	7.34e-06	0.000326	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2RA—Graves' disease	7.31e-06	0.000324	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD4—Graves' disease	7.27e-06	0.000323	CbGpPWpGaD
Sorafenib—RAF1—Disease—HLA-A—Graves' disease	7.14e-06	0.000317	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—B3GNT2—Graves' disease	7.14e-06	0.000317	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL10—Graves' disease	7.08e-06	0.000314	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-DRB1—Graves' disease	7.07e-06	0.000313	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—B3GNT2—Graves' disease	6.97e-06	0.000309	CbGpPWpGaD
Sorafenib—KIT—Immune System—IFNG—Graves' disease	6.79e-06	0.000301	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IFNG—Graves' disease	6.79e-06	0.000301	CbGpPWpGaD
Sorafenib—RAF1—Immune System—ICAM1—Graves' disease	6.78e-06	0.000301	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1B—Graves' disease	6.72e-06	0.000298	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2RA—Graves' disease	6.66e-06	0.000295	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2RA—Graves' disease	6.66e-06	0.000295	CbGpPWpGaD
Sorafenib—BRAF—Disease—CD4—Graves' disease	6.65e-06	0.000295	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL10—Graves' disease	6.62e-06	0.000293	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—B3GNT2—Graves' disease	6.57e-06	0.000291	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD4—Graves' disease	6.56e-06	0.000291	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD4—Graves' disease	6.56e-06	0.000291	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	6.55e-06	0.00029	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—B3GNT2—Graves' disease	6.51e-06	0.000289	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—Graves' disease	6.5e-06	0.000288	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IFNG—Graves' disease	6.45e-06	0.000286	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IFNG—Graves' disease	6.43e-06	0.000285	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2RA—Graves' disease	6.32e-06	0.00028	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2RA—Graves' disease	6.3e-06	0.000279	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD4—Graves' disease	6.23e-06	0.000276	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—Graves' disease	6.21e-06	0.000275	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1B—Graves' disease	6.06e-06	0.000269	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1B—Graves' disease	6.06e-06	0.000269	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—Graves' disease	6.06e-06	0.000269	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFNG—Graves' disease	5.79e-06	0.000257	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1B—Graves' disease	5.75e-06	0.000255	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—Graves' disease	5.75e-06	0.000255	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1B—Graves' disease	5.73e-06	0.000254	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—Graves' disease	5.73e-06	0.000254	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL10—Graves' disease	5.71e-06	0.000253	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2RA—Graves' disease	5.68e-06	0.000252	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GC—Graves' disease	5.67e-06	0.000251	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—Graves' disease	5.59e-06	0.000248	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—B3GNT2—Graves' disease	5.57e-06	0.000247	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2RA—Graves' disease	5.41e-06	0.00024	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—Graves' disease	5.17e-06	0.000229	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—Graves' disease	5.16e-06	0.000229	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—Graves' disease	5.16e-06	0.000229	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2RA—Graves' disease	5.06e-06	0.000224	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—Graves' disease	4.99e-06	0.000221	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—Graves' disease	4.6e-06	0.000204	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—Graves' disease	4.6e-06	0.000204	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2RA—Graves' disease	4.37e-06	0.000194	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—B3GNT2—Graves' disease	4.3e-06	0.00019	CbGpPWpGaD
